Incanthera (INC) is a spin-out from the Institute of Cancer Therapeutics (ICT) at the University of Bradford to exploit development opportunities generated by ICT. This has provided the company with its core pro-drug delivery platform technology, to which additional technologies/products have been acquired, all focused on producing better clinical outcomes for cancer patients. With the new capital raised when it listed on the Aquis Growth Exchange in February 2020, INC has further advanced the development of its refined Sol formulation towards the point where it can be out-licensed to a partner for commercialisation.
